Hermes Pardini reinforces oncology space with acquisition
In its fourth M&A move in 2022, the diagnostic medicine group from Minas Gerais buys HSB, a laboratory specializing in high-complexity tests for oncology diagnosis
Pending approval from the Administrative Council for Economic Defense (Cade) for the merger with Fleury, announced in June this year and valued at R$ 2.5 billion, Hermes Pardini remains active in the field of M&As.
The diagnostic medicine group from Minas Gerais has just announced the acquisition of 100% of the share capital of HSB, a laboratory specializing in pathological anatomy, cytopathology and immunohistochemistry – highly complex diagnostic tests in oncology, in an agreement that evaluates the asset at BRL 11 million.
Headquartered in Belo Horizonte (MG), HSB was founded in 1969 by pathologist Hugo Silviano Brandão and will keep partner Laura Silviano Brandão in charge of the operation. Hermes Pardini highlighted that the purchase of the “countryside” company reinforces and expands its borders in one of the lines of its portfolio.
“The merger favors the expansion of the Pardini Group’s Pathological Anatomy business unit by joining a strong and recognized brand in this market, adding experienced and recognized pathologists, and expanding access to high-complexity exams for the diagnosis of cancers”, informed the group.
In a relevant fact, Hermes Pardini also highlighted that the investment brings an infrastructure gain in a highly specialized production unit and involves synergies with other brands of the group, in addition to opening the way for logistical cost reductions and the expansion of the collection of anatomical exams. -pathological.
At the same time, the company stressed in the statement that the Pathological Anatomy operation is one of the gateways to Personalized Medicine, another relevant line in the group’s portfolio.
This is the fourth move within Hermes Pardini’s inorganic strategy in 2022. In addition to the merger with Fleury and this Tuesday’s agreement, the group announced the purchase of CSV, in Espírito Santo, in September; and the acquisition of the DaVita Health Care network, in São Paulo, in February.
With the release of its third quarter balance scheduled for next week, Pardini reported gross revenue of R$ 558.7 million between April and June of this year, in addition to a record volume of 41.1 million exams in the period.
The company is valued at R$ 2.91 billion. Its shares closed this Tuesday’s trading session at R$22.99, down 1.12%. In the accumulated of 2022, however, the papers recorded an appreciation of 19.1%.